SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-21-004932
Filing Date
2021-04-27
Accepted
2021-04-27 16:49:01
Documents
4
Period of Report
2021-06-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20210624xdef14a.htm DEF 14A 560806
2 GRAPHIC tmb-20210624xdef14a003.jpg GRAPHIC 167763
3 GRAPHIC tmb-20210624xdef14a002.jpg GRAPHIC 171884
4 GRAPHIC tmb-20210624xdef14a001.jpg GRAPHIC 8538
  Complete submission text file 0001558370-21-004932.txt   1041655
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39746 | Film No.: 21859654
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences